AP2010005512A0 - Novel compounds active as muscarinic receptor antagonists. - Google Patents

Novel compounds active as muscarinic receptor antagonists.

Info

Publication number
AP2010005512A0
AP2010005512A0 AP2010005512A AP2010005512A AP2010005512A0 AP 2010005512 A0 AP2010005512 A0 AP 2010005512A0 AP 2010005512 A AP2010005512 A AP 2010005512A AP 2010005512 A AP2010005512 A AP 2010005512A AP 2010005512 A0 AP2010005512 A0 AP 2010005512A0
Authority
AP
ARIPO
Prior art keywords
receptor antagonists
novel compounds
muscarinic receptor
compounds active
active
Prior art date
Application number
AP2010005512A
Other languages
English (en)
Inventor
Charlotte Alice Louise Lane
Paul Alan Glossop
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AP2010005512A0 publication Critical patent/AP2010005512A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2010005512A 2008-07-15 2009-07-01 Novel compounds active as muscarinic receptor antagonists. AP2010005512A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8072608P 2008-07-15 2008-07-15
PCT/IB2009/052859 WO2010007552A1 (en) 2008-07-15 2009-07-01 Novel compounds active as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
AP2010005512A0 true AP2010005512A0 (en) 2010-12-31

Family

ID=41139473

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2010005512A AP2010005512A0 (en) 2008-07-15 2009-07-01 Novel compounds active as muscarinic receptor antagonists.

Country Status (28)

Country Link
US (1) US20100016366A1 (xx)
EP (1) EP2328868A1 (xx)
JP (1) JP2011528346A (xx)
KR (1) KR20110017452A (xx)
CN (1) CN102099334A (xx)
AP (1) AP2010005512A0 (xx)
AR (1) AR072802A1 (xx)
AU (1) AU2009272303B2 (xx)
BR (1) BRPI0915753A2 (xx)
CA (1) CA2727769A1 (xx)
CL (1) CL2011000093A1 (xx)
CO (1) CO6321246A2 (xx)
CR (1) CR11828A (xx)
DO (1) DOP2011000017A (xx)
EA (1) EA201001842A1 (xx)
EC (1) ECSP11010753A (xx)
HN (1) HN2009001330A (xx)
IL (1) IL210293A0 (xx)
MA (1) MA32479B1 (xx)
MX (1) MX2011000588A (xx)
NI (1) NI201100015A (xx)
NZ (1) NZ589934A (xx)
PE (1) PE20110312A1 (xx)
SV (1) SV2011003808A (xx)
TW (1) TW201006799A (xx)
UY (1) UY31980A (xx)
WO (1) WO2010007552A1 (xx)
ZA (1) ZA201100841B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083387A1 (en) * 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
CN102939008A (zh) * 2010-04-01 2013-02-20 塞拉维达公司 改善睡眠质量的方法
WO2016155573A1 (zh) * 2015-03-27 2016-10-06 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
TW201702225A (zh) * 2015-05-14 2017-01-16 Sichuan Haisco Pharmaceutical Co Ltd 具有β２受體激動及Ｍ受體拮抗活性的含氮雜螺環衍生物及其在醫藥上的用途
CN106336406B (zh) * 2015-07-10 2020-01-03 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的八氢并环戊二烯衍生物及其在医药上的用途
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP2013172A4 (en) * 2006-04-24 2010-08-04 Astrazeneca Ab NEW ALKYLESTERS FROM CYCLIC AMINO ALCOHOLS WITH MUSCARIN M3 RECEPTORANTAGONOSTIC ACTIVITY FOR THE TREATMENT OF CHRONIC BRONCHIA SUPPRESSION, ASTHMA OR OVERACTIVE HARNBASE

Also Published As

Publication number Publication date
AR072802A1 (es) 2010-09-22
UY31980A (es) 2010-02-26
HN2009001330A (es) 2012-04-02
CL2011000093A1 (es) 2011-05-06
IL210293A0 (en) 2011-03-31
NZ589934A (en) 2012-06-29
US20100016366A1 (en) 2010-01-21
EP2328868A1 (en) 2011-06-08
DOP2011000017A (es) 2011-02-15
AU2009272303B2 (en) 2011-12-22
CO6321246A2 (es) 2011-09-20
TW201006799A (en) 2010-02-16
KR20110017452A (ko) 2011-02-21
JP2011528346A (ja) 2011-11-17
CA2727769A1 (en) 2010-01-21
SV2011003808A (es) 2011-03-23
BRPI0915753A2 (pt) 2015-11-03
EA201001842A1 (ru) 2011-08-30
CN102099334A (zh) 2011-06-15
MA32479B1 (fr) 2011-07-03
WO2010007552A1 (en) 2010-01-21
PE20110312A1 (es) 2011-06-25
ZA201100841B (en) 2011-10-26
NI201100015A (es) 2011-08-05
CR11828A (es) 2011-01-10
MX2011000588A (es) 2011-03-01
ECSP11010753A (es) 2011-02-28
AU2009272303A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
ZA201001597B (en) Octahydropentalene compounds as chemokine receptor antagonists
IL212551A0 (en) Cxcr4 receptor compounds
ZA201100625B (en) Azaindazole compounds as ccr1 receptor antagonists
EP2099454A4 (en) AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
EP2091533A4 (en) CONTAINING SPIROCYCLIC COMPOUNDS AS ANTAGONISTS OF CGRP RECEPTORS
EP2141990A4 (en) ACTIVE COMPOUNDS ON 11BETA-HSD1
AP2011005817A0 (en) Substituted piperidines as CCR3 antagonists.
SG158918A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
IL196587A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
AP2010005364A0 (en) Novel heterocyclic compounds.
BRPI0815797A2 (pt) Compostos 8-azabiciclo[3.2.1]octil-2-hidroxibanzamida como antagonistas de receptor opióide mu
IL209318A0 (en) Bicyclic compounds having activity at the cxcr4 receptor
EP2254413A4 (en) IMIDAZOBENZAZEPIN-CGRP receptor antagonists
ZA201001125B (en) Pyrrolidine Aryl-Ether as NK3 receptor antagonists
ZA201000676B (en) Pyrrolidine aryl-ether as NK3 receptor antagonists
IL199922A0 (en) Quaternary ammonium diphenylamethyl compounds useful as muscarinic receptor antagonists
IL209264A0 (en) Heteroaromatic monoamides as orexinin receptor antagonists
IL198542A0 (en) 2-aminoquinolines as 5-ht(5a)receptor antagonists
ZA201100841B (en) Novel compounds active as muscarinic receptor antagonists
ZA201007988B (en) Quinuclidine derivatives as muscarinic m3 receptor antagonists
EP2365748A4 (en) IMIDAZOISOINDOLA ANTAGONISTS OF NEUROPEPTIDE S RECEPTORS
EP2120564A4 (en) BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS
EP2341919A4 (en) CGRP RECEPTOR ANTAGONISTS
EP2340025A4 (en) CGRP RECEPTOR ANTAGONISTS